Markman on Oncology

• Immunotherapy Toxicity: How Much Do Physicians Know?   Maurie Markman, MD, discusses physician awareness of immune-related adverse events associated with immune checkpoint inhibitors.
  Medscape Oncology, March 15, 2023
• Cancer Statistics: Public Health Improvements and Future Thoughts   Maurie Markman, MD, discusses the most recent paper describing cancer statistics.
  Medscape Oncology, March 07, 2023
• Advanced Ovarian Cancer: 20% Disease-Free Survival at 10 Years   Maurie Markman, MD, discusses a recent paper on the 10-year survival rate of patients with stage III ovarian cancer.
  Medscape Oncology, February 07, 2023
• Is Trametinib a New Standard for Low-Grade Serous Ovarian Cancer?   Is it possible that a new standard of care is emerging in low-grade serous ovarian cancer? Dr Maurie Markman discusses a study that shows clear benefit with trametinib.
  Medscape Oncology, January 25, 2023
• Behavioral Modification Could Prevent Nearly 50% of Cancer Deaths   Maurie Markman, MD, discusses findings from a recent article demonstrating that nearly half of all cancer deaths could be prevented with behavioral modification.
  Medscape Oncology, December 14, 2022
• Bariatric Surgery Reduces Obesity-Related Cancer Risk   Maurie Markman, MD, discusses results from a case-control study of individuals with high BMI, demonstrating reduced obesity-related cancer risk following bariatric surgery.
  Medscape Oncology, December 12, 2022
• SOLO1: 7-Year Follow-up Highlights the Value of Maintenance Olaparib   Maurie Markman, MD, discusses 7-year follow-up results of the SOLO1 study in patients with advanced ovarian cancer and a BRCA mutation.
  Medscape Oncology, December 12, 2022
• Reassuring Data: Olaparib Dose Reductions Have Minimal Effect   Dr Maurie Markman discusses a recent paper describing olaparib interruptions and dose reductions in ovarian cancer.
  Medscape Oncology, September 14, 2022
• Ovarian Cancer Is Not Silent: Common, Nonspecific Symptoms   Dr Maurie Markman discusses a recent publication on the symptoms of early-stage, high-risk ovarian cancer.
  Medscape Oncology, September 13, 2022
• Synergy With Combo Checkpoint Inhibitors: Fact or Fiction?   Dr Maurie Markman highlights a new paper questioning whether there is synergy among checkpoint inhibitors used in combination.
  Medscape Oncology, July 27, 2022
• Single-Dose HPV Vaccination Strategy May Be Coming   Are we being single-minded about cervical cancer prevention? Hear Dr Maurie Markman discuss a pivotal paper that says one dose of an HPV vaccine may be enough.
  Medscape Oncology, July 26, 2022
• Gynecologic Cancer Studies: What to Look for at ASCO 2022   It's not just about ovarian cancer anymore -- presentations at ASCO 2022 illustrate the major advances that have been made in gynecologic cancer treatments.
  Medscape Oncology, May 20, 2022
• Young Adult Obesity Has Quintupled. Will 'Cancer Wave' Follow?   Maurie Markman discusses a recent article highlighting obesity prevalence among young adults with an eye toward the implications for cancer incidence in the United States.
  Medscape Oncology, May 09, 2022
• Cancer Data Reproducibility Problem Undermines Public Trust   Dr Maurie Markman discusses problems with the replicability of research published in high-impact medical journals and the potential implications.
  Medscape Oncology, April 27, 2022
• Physical Activity Reduces Cognitive Decline in Breast Cancer   Dr Maurie Markman discusses a recent paper on the use of physical activity to decrease cognitive decline in patients with breast cancer.
  Medscape Oncology, March 07, 2022
• The Impact of HPV Vaccination on Cervical Cancer   Dr Maurie Markman discusses recent data on HPV vaccination and trends in cervical cancer incidence and mortality.
  Medscape Oncology, March 04, 2022
• ASCO 2021 ASCO Data Confirm Standard of Care for Cervical, Ovarian Cancer   Dr Maurie Markman describes two large phase 3 trials that 'clearly establish' the existing standard of care for cervical and ovarian cancer.
  Medscape Oncology, July 09, 2021
• 'High-Speed' Science: It's Time We Slow Down   With COVID studies and virtual meeting abstracts coming fast and furious, we need to slow down and return to carefully reviewing new data, says Maurie Markman.
  Medscape Oncology, December 01, 2020
• Ovarian Cancer Trials: The Good News and the Bad News   Dr Maurie Markman describes two trials that may shift the paradigm for ovarian cancer treatment but also notes that we are continuing to let down our patients by failing to test for BRCA mutations.
  Medscape Oncology, August 19, 2020
• New Options for Rare Cancer Mutations: Basket and 'Just-in-Time' Trials   Basket trials and 'just in time' trials are two new options to target actionable genetic mutations in cancer, regardless of tumor type.
  Medscape Oncology, May 08, 2020